Business Monitor International

Botswana Pharmaceuticals & Healthcare Report

Published 02 June 2014

  • 62 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
Botswana Pharmaceuticals & Healthcare Report

BMI View: We remain relatively optimistic over the growth potential of Botswana's pharmaceutical and healthcare sector, given the government's aim to improve healthcare. However, implementation of these healthcare aims remain a risk, as issues such as counterfeit pharmaceuticals and expired products highlights issues in drug procurement, thereby limiting healthcare access.

While Botswana offers a relatively stable environment for pharmaceutical and healthcare investors, low per-capita pharmaceutical and healthcare expenditure will remain a key downside risk to the development of the sector. In addition, the overall Sub-Saharan Africa region has low expenditure on healthcare and pharmaceutical, making it less likely that firms will invest in the region.

Headline Expenditure Projections

Pharmaceuticals: BWP1.60bn (USD193mn) in 2013 to BWP1.74bn (USD201mn) in 2014; +7.2% in local currency terms and 4.0% in US dollar terms. Forecast broadly in line with Q214.

Healthcare: BWP7.42bn (USD884mn) in 2013 to BWP8.24bn (USD952mn) in 2014; +11.0% in local currency terms and +7.7% in US dollar terms. Forecast broadly in line with Q214.

Risk/Reward Rating

Botswana's Pharmaceutical Risk/Reward Rating (RRR) score for Q314 is 39.5 - slightly lower than the MEA region's score of 42.4, placing it 17 out of 30 countries in the region. We note that the country has above average scores of 7.7 and 8.1 respectively for Industry Risks and Ccountry Risks scores.

Key Trends And Developments

  • In March 2014, Botswana's Minister of Health Dr John Seakgosing said a telemedicine project between Ghanzi Primary Hospital and Princess Marina Hospital has been a success, as it allows doctors in Ghanzi Primary Hospital (which has no specialist radiologists) to send X-ray images to Princess Marina Hospital for interpretation and feedback of more complex medical cases. The roll-out of such projects will also be considered in the near future when teleradiography challenges, such as maintenance...

Table of Contents

BMI Industry View
Business Environment
Industry Forecast
Overall Market Forecast
Table: Pharmaceutical Sales Indicators, 2009-2017
Healthcare Expenditure Forecast
Table: Table: HIV Prevalence In Africa
Table: Healthcare Expenditure Indicators, 2009-2017
Table: Healthcare Governmental Indicators, 2009-2017
Table: Healthcare Private Indicators, 2009-2017
Economic Analysis
Industry Risk Reward Ratings
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q213
Market Overview
Table: Overall Market Size Is Small But Individual Expenditure Is Relatively High
Regulatory Development
Intellectual Property Issues
Research & Development
Company Profile
Gemi Pharmacure
Demographic Forecast
Table: Botswana's Population By Age Group, 1990-2020 ('000)
Table: Botswana's Population By Age Group, 1990-2020 (% of total)
Table: Botswana's Key Population Ratios, 1990-2020
Table: Botswana's Rural And Urban Population, 1990-2020
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

The Botswana Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Botswana Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Botswanan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Botswana to test other views - a key input for successful budgeting and strategic business planning in the Botswanan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Botswanan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Botswana.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.


BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%


'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc